文献速递骨质疏松与钙磷/甲状旁腺

硬骨抑素抑制的心血管安全性

Cardiovascular Safety and Sclerostin Inhibition.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

硬骨抑素由骨细胞产生,抑制经典Wnt通路并刺激RANKL释放;romosozumab作为抗硬骨抑素抗体,在临床试验中增加骨密度并降低骨折风险。两项大型绝经后骨质疏松试验显示,与安慰剂比心血管事件发生率相似,但与阿仑膦酸钠比严重心血管事件发生率更高;临床使用需权衡心血管风险与获益。

要点

  • 与安慰剂相比,romosozumab心血管事件发生率相似。
  • 与阿仑膦酸钠相比,romosozumab严重心血管事件发生率更高。
  • 高骨折风险的绝经后骨质疏松女性使用前需仔细评估心血管风险与获益。

核心结论

  • 无临床前或遗传学证据表明抑制硬骨抑素对心血管安全有害,但大型绝经后女性临床试验证据存在矛盾。
  • romosozumab应仅在高骨折风险的绝经后骨质疏松女性中,仔细考虑心血管风险及获益平衡后使用。

研究设计与样本

  • 基于两项大型绝经后女性骨质疏松临床试验的心血管安全性裁定分析,并整合临床前与遗传学研究。

主要发现

  • 与安慰剂相比,两组心血管事件发生率相似。
  • 与阿仑膦酸钠相比,romosozumab组严重心血管事件发生率更高。
  • 严重心血管不良事件发生率低,事后分析需谨慎解读;相对风险似乎不受既存心血管疾病或危险因素影响。

临床怎么用

  • 对高骨折风险的绝经后骨质疏松女性,使用romosozumab前应仔细评估心血管风险并权衡获益与风险。

局限性

  • 严重心血管不良事件发生率低,事后分析应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sclerostin, which is primarily produced by the osteocytes, inhibits the canonical Wnt pathway and thereby the osteoblasts and stimulates RANKL release by the osteocytes and thereby osteoclast recruitment. Inhibition of sclerostin therefore causes stimulation of bone formation and inhibition of resorption. In clinical trials, romosozumab, an antibody against sclerostin, increases bone mineral density and reduces the risk of fractures compared with placebo and alendronate. The cardiovascular safety of romosozumab was adjudicated in 2 large clinical osteoporosis trials in postmenopausal women. Compared with placebo, the incidence of cardiovascular events was similar in the 2 treatment groups. Compared with alendronate, the incidence of serious cardiovascular events was higher in women treated with romosozumab. The incidence of serious cardiovascular adverse events was low and post hoc analyses should therefore be interpreted with caution; however, the relative risk seemed unaffected by preexisting cardiovascular disease or risk factors. Sclerostin is expressed in the vasculature, predominantly in vascular smooth muscle cells in the media. However, preclinical and genetic studies have not demonstrated any increased cardiovascular risk with continuously low sclerostin levels or inhibition of sclerostin. Furthermore, no potential mechanisms for such an effect have been identified. In conclusion, while there is no preclinical or genetic evidence of a harmful effect of sclerostin inhibition on cardiovascular safety, the evidence from the large clinical trials in postmenopausal women is conflicting. Romosozumab should therefore be used for the treatment of postmenopausal women with osteoporosis at high risk of fracture after careful consideration of the cardiovascular risk and the balance between benefits and risks.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Langdahl BL, Hofbauer LC, Forfar JC, et al. Cardiovascular Safety and Sclerostin Inhibition. J Clin Endocrinol Metab. 2021. PMID: 33755157. doi:10.1210/clinem/dgab193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。